Who founded MBX Biosciences?

MBX Biosciences was founded by Richard DiMarchi, Peter Kent Hawryluk in 2019.

Who are MBX Biosciences's investors?

MBX Biosciences's investors include Frazier Life Sciences, Norwest Venture Partners, IU Ventures, New Enterprise Associates (NEA), OrbiMed.

How much funding has MBX Biosciences raised?

MBX Biosciences has disclosed $74.8M raised across 3 rounds.

Where is MBX Biosciences headquartered?

MBX Biosciences is headquartered in Carmel, US.

MBX Biosciences

Carmel, US · Founded 2019 · 5 known investors

mbxbio.com ↗

MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.

BiotechHealthtech

Founders & leadership

MBX Biosciences was founded in 2019 by Richard DiMarchi and Peter Kent Hawryluk.

Richard DiMarchiCo-founder

Peter Kent HawrylukCo-founder

Timothy KnickerbockerExecutive

Steve HoerterChairman & Chief Executive Officer

Salomon AzoulayChief Medical Officer

Karen BasbaumChief Business Officer

Michelle GrahamChief Human Resources Officer

John SmitherChief Financial Officer

Mark SouedChief Commercial Officer

Investors · 5

Frazier Life Sciences✓ verifiedPalo Alto

Norwest Venture Partners✓ verifiedMenlo Park · $10M – $30M

IU VenturesBloomington

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

OrbiMedNew York · $1M – $75M

Reported raises · per SEC filings

Form D private placements

$74.8M disclosed across 3 rounds · 2019–2022

▶$46.7MraisedNov 2022 · 20 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

James M. CorneliusDirector
Patrick HeronDirector
Edward MathersDirector
Richard DiMarchiExecutive Officer, Director
Tiba AynechiDirector
Peter Kent HawrylukExecutive Officer, Director
Ora PescovitzDirector
Carl GordonDirector
Richard BartramExecutive Officer

Offering amount: $115.2M
Amount sold: $46.7M
First sale: Nov 2022
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25.8MraisedJul 2020 · 16 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Timothy KnickerbockerExecutive Officer, Director
Richard DiMarchiExecutive Officer, Director
Peter Kent HawrylukExecutive Officer, Director

Offering amount: $35.8M
Amount sold: $25.8M
First sale: Jul 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.3MraisedMay 2019 · 9 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Richard DiMarchiExecutive Officer, Director
Timothy KnickerbockerExecutive Officer, Director
Peter Kent HawrylukExecutive Officer, Director

Offering amount: $5M
Amount sold: $2.3M
First sale: Apr 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does MBX Biosciences do?: MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.
Who founded MBX Biosciences?: MBX Biosciences was founded by Richard DiMarchi, Peter Kent Hawryluk in 2019.
Who are MBX Biosciences's investors?: MBX Biosciences's investors include Frazier Life Sciences, Norwest Venture Partners, IU Ventures, New Enterprise Associates (NEA), OrbiMed.
How much funding has MBX Biosciences raised?: MBX Biosciences has disclosed $74.8M raised across 3 rounds.
Where is MBX Biosciences headquartered?: MBX Biosciences is headquartered in Carmel, US.